Is this bad news for CSL shares?

Should you be worried by this trial news?

| More on:
man with his hand on his chin wondering about the AIM share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

CSL Limited (ASX: CSL) shares are edging lower on Tuesday.

In morning trade, the biotherapeutics giant's shares are down 0.5% to $257.50.

What's weighing on its shares?

Today's weakness may be down to news that a competing treatment has delivered strong trial results.

Overnight, the Argenx SE (NASDAQ: ARGX) share price rocketed 28% on Wall Street after reporting positive topline data from the ADHERE study of Vyvgart Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Argenx said:

CIDP is a chronic, progressive autoimmune disease that can cause substantial disability in those affected, often leading to impaired ambulation or difficulty completing normal daily tasks without help. The positive ADHERE data show that VYVGART Hytrulo may represent a new patient-forward treatment option that can prevent symptom deterioration while minimizing side effects and treatment burden.

The ADHERE study is the largest clinical trial of CIDP patients to date, enrolling adults who were treatment naïve or currently on immunoglobulin therapy or corticosteroids.

Is this bad news for CSL shares?

This news could potentially be bad news for CSL and its shares due to the significant revenue it generates from its immunoglobulin therapies. In response to the trial, Goldman Sachs said:

ARGX has reported the top-line data from its ADHERE study, evaluating Vyvgart (first-in-class FcRn inhibitor) for safety and efficacy in the treatment of chronic immune demyelinating polyneuropathy (CIDP), the indication responsible for 25-35% of IG demand (IG is currently the most important protein derived from plasma fractionation, constituting 37% of CSL's FY23E revenue forecasts and 56% of growth FY23-26E).

Our Argenx analyst currently forecasts peak sales of $1,921mn/$1,248mn (unadjusted/risk-adjusted) in 2035 for Vyvgart in CIDP.

The good news is that the team at UBS don't believe that Vyvgart will have an overly large impact on CSL's revenue. It sees the worst-case scenario as a ~3% revenue hit. Though, even then, the broker feels that is unlikely.

As a result, it may be unnecessary to worry too much about this news. And with UBS retaining its buy rating and $340.00 price target, it could prove to be an opportune time to pick up CSL shares while they are cheap.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »